Royalty Pharma plc


SKU: RPRX-1 Category:


Royalty Pharma: Identifying and Investing in Future Fields of Biopharma Innovation! 


Within the first quarter of 2024, Royalty Pharma displayed impressive performance, managing 14% growth in royalty receipts, thereby underlining the benefits of its diversified portfolio encompassing over 35 commercial products. However, it is important to note a decline for milestones and other contractual payments, which were mainly affected by a high base of the year-ago quarter due to a single nonrecurring Biohaven-related payment. Portfolio Receipts, as a result, decreased to $717 million, aligning with the company’s expectations. For capital allocation, Royalty Pharma announced a transaction that is expected to raise its capital deployment to approximately $670 million, involving the acquisition of royalties and milestones on Sanofi’s frexalimab, costing approximately $525 million, which includes estimated transaction costs. Sanofi’s frexalimab is an exciting development stage drug with potential multi-blockbuster opportunities in multiple sclerosis and other immune indications.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!